Paloma Partners Management Co raised its holdings in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 35.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,495 shares of the company’s stock after buying an additional 6,145 shares during the quarter. Paloma Partners Management Co’s holdings in Medidata Solutions were worth $1,489,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently modified their holdings of MDSO. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Medidata Solutions by 11.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,534 shares of the company’s stock valued at $666,000 after purchasing an additional 847 shares during the last quarter. Essex Investment Management Co. LLC lifted its position in Medidata Solutions by 8.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 11,085 shares of the company’s stock valued at $702,000 after acquiring an additional 886 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Medidata Solutions by 48.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock valued at $205,000 after acquiring an additional 1,056 shares in the last quarter. Swiss National Bank lifted its position in Medidata Solutions by 1.2% in the 3rd quarter. Swiss National Bank now owns 97,600 shares of the company’s stock valued at $7,619,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in Medidata Solutions by 6.0% in the 3rd quarter. Advisors Asset Management Inc. now owns 21,792 shares of the company’s stock valued at $1,701,000 after acquiring an additional 1,235 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
In other Medidata Solutions news, CEO Tarek Sherif sold 26,836 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $70.25, for a total value of $1,885,229.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Rouven Bergmann sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $70.00, for a total transaction of $210,000.00. Following the transaction, the chief financial officer now owns 84,775 shares of the company’s stock, valued at approximately $5,934,250. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,836 shares of company stock valued at $2,495,689. Insiders own 5.80% of the company’s stock.
Several equities analysts have recently weighed in on the company. TheStreet raised Medidata Solutions from a “c+” rating to a “b-” rating in a report on Monday, March 12th. BidaskClub raised Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. ValuEngine lowered Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Saturday, March 17th. Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Finally, Deutsche Bank initiated coverage on Medidata Solutions in a research report on Friday, December 8th. They set a “buy” rating and a $78.00 price objective for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $82.07.
Shares of MDSO traded down $0.35 during trading hours on Friday, reaching $63.74. 483,942 shares of the company traded hands, compared to its average volume of 476,070. The firm has a market capitalization of $3,796.26, a PE ratio of 74.99, a price-to-earnings-growth ratio of 3.37 and a beta of 1.53. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.49 and a quick ratio of 1.49. Medidata Solutions Inc has a 12-month low of $59.22 and a 12-month high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, February 8th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $141.20 million during the quarter, compared to the consensus estimate of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 earnings per share. research analysts anticipate that Medidata Solutions Inc will post 0.93 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Medidata Solutions Inc (MDSO) Stake Boosted by Paloma Partners Management Co” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/paloma-partners-management-co-grows-stake-in-medidata-solutions-inc-mdso.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.